Pharmaceuticals, Biotechnology and Life Sciences
Merck has ensured Breakthrough Therapy Designation for the investigational targeted therapy tepotinib in USA, for patients with metastatic non-small cell lung cancer (NSCLC) harboring MET exon 14 skipping alterations who progressed following platinum-based cancer therapy.
HYDERABAD, India & PRINCETON, N.J.–(BUSINESS WIRE)–Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together…
LOS ANGELES–(BUSINESS WIRE)–Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) has…
Prices projected to increase over previous estimates, driven by newly released products such as cellular and gene therapies CHARLOTTE, N.C.–(BUSINESS…
Glenmark Pharmaceuticals said Tuesday it has bagged the final USFDA’s approval for its generic version of Mylan’s Olux-E Foam, Clobetasol Propionate Foam.
Longest survival follow-up from a pooled analysis of randomized Phase 3 trials of an Immuno-Oncology therapy in this setting demonstrated…
Merck, a leading science and technology company, today announced the initiation of two global pivotal Phase III trials (EVOLUTION RMS 1 and 2) studying the efficacy and safety of evobrutinib, an oral, highly selective Bruton’s Tyrosine Kinase (BTK) inhibitor in adult patients with relapsing multiple sclerosis (RMS).
First approval for Xeris is based on positive efficacy and safety results from multiple clinical studies GVOKE is the first…
BOSTON–(BUSINESS WIRE)–Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will present at the Morgan Stanley Global Healthcare Conference on…
— The Company’s GPR174 Inhibitors Enhance Anti-Tumor Activities of Adenosine Pathway Inhibitors by up to 25-Fold — SEATTLE–(BUSINESS WIRE)–Omeros Corporation…